Glenmark and BeiGene Partner to Bring Innovative Cancer Therapies to India

Mumbai, India – May 21, 2024 – Glenmark Pharmaceuticals Ltd. (Glenmark), a global research-driven pharmaceutical company, today announced an exclusive marketing and distribution agreement with BeiGene, a leading oncology company. This collaboration will bring BeiGene’s novel cancer treatments, Tislelizumab and Zanubrutinib, to patients in India.

“We are excited about this partnership with BeiGene,” said Alok Malik, President and Business Head of India Formulations at Glenmark. “The addition of Tislelizumab and Zanubrutinib to our oncology portfolio strengthens our commitment to providing access to advanced cancer therapies for patients across India.”

“This collaboration reflects our shared vision of improving healthcare access throughout Asia,” said Adam Roach, Vice President and Head of Asia-Pacific at BeiGene. “We are dedicated to increasing access to essential treatments, especially in countries like India with a significant cancer burden.”

Addressing the Growing Cancer Burden in India

India has the world’s third-highest number of cancer cases, with predictions suggesting this number will continue to rise. This partnership aims to address this critical need by providing access to innovative cancer therapies.

About the Treatments

  • Tislelizumab: A monoclonal antibody designed to fight tumors by enhancing the body’s immune response.
  • Zanubrutinib: A small molecule inhibitor that targets a specific protein involved in the growth of cancer cells.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company with a presence in branded, generic, and OTC segments. The company focuses on respiratory, dermatology, and oncology therapeutic areas.

About BeiGene

BeiGene is a global oncology company developing innovative and affordable cancer treatments for patients worldwide.

Leave a Reply

Your email address will not be published. Required fields are marked *